Outcome of patients with glioblastoma in Saudi Arabia: Single center experience.
Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is associated with one of the worst 5 year survival rates among all human cancer types. To date, no published data are available for the outcome of this disease in Saudi Arabia. The present study performed a single-center, retrospective cohort study to evaluate the outcome of patients with GBM in Saudi Arabia. The Comprehensive Cancer Center at King Fahad Medical city (Riyadh, Saudi Arabia) was used in the present study. All adult patients (≥18 years) diagnosed with histologically proven GBM between January 2008 and December 2013 were included in the present study. A total of 90 patients were treated during the specified period. Of this, 73 (81%) patients underwent resection and 17 (19%) had biopsy only. The majority of patients (n=88; 98%) received radiotherapy (XRT): 67 (76%) with standard and 21 (24%) with hypo-fractionated dosage. Of the total patients, 65 (72%) received combined modality therapy [standard XRT concurrently with Temozolmide (TMZ)]. The 6 month progression-free survival rate was 43% for all patients and 55% for the combined modality subgroup. The median overall survival (OS) for all patients was 13.7 months. However, the median OS for patients treated with combined modality was 19.7 months. In this single-center retrospective study, the outcomes of patients with GBM were similar to those in previously reported studies. An improved outcome was associated with an improved performance status, absence of residual disease and use of adjuvant TMZ.
Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Abdullah K
AK
Altwairgi
Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Waleed
W
Algareeb
Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Gaaem
G
Yahya
Radiation Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia; Clinical Oncology and Nuclear Medicine Department, Sohag University, Sohag 11432, Egypt.
Ahmed M
AM
Maklad
Radiation Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia; Radiotherapy and Nuclear Medicine Department, South Egypt Cancer Institute, Assiut University, Assiut 71515, Egypt.
Moamen Mom
MM
Aly
Pathology and Clinical Laboratory Medicine Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Wafa
W
Al Shakweer
Radiation Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Ali
A
Balbaid
Radiation Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Eyad
E
Alsaeed
Radiation Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Hussain
H
Alhussain
National Neuroscience Institute, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Yassir
Y
Orz
National Neuroscience Institute, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Ahmed
A
Lary
Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia.
Ashraf
A
Elyamany
brain tumor; glioblastoma multiforme; median overall survival; radiotherapy; temozolmide